As per the 2015 IMS report, global biologics market is projected to reach 28% of the global pharmaceuticals market by 2020. This would translate to the biologics´ 20202 market forecast of USD 390 billion. As many of the biologics will face patent expiration in the next 5 years, the market potential of biosimilars is forecasted at USD 20 billion by 2020. Furthermore, the cumulative potential savings to health systems in the five major European Union (EU) markets and the United States (US), as a result of the use of biosimilars, could exceed EUR 50 billion in aggregate over the next five years and reach as much as EUR100 billion depending upon the magnitude of price reduction over reference biologic.